Alpine Immune Sciences

Alpine Immune Sciences Current Liabilities

Delisted

The Current Liabilities of Alpine Immune Sciences (ALPN) as of Nov 17, 2026 is 47.79 M USD. In the previous year, Current Liabilities was 40.63 M USD — a change of 17.64% (higher).

Current Liabilities

47.79 MUSD

YoY

17.64%

Last updated:

Current Liabilities of Alpine Immune Sciences is 2023 47.79 M USD. Current Liabilities of Alpine Immune Sciences was 2022 40.63 M USD. It decreases by 17.64% higher compared to the previous year.

The Alpine Immune Sciences Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2016
11.10 M USD
Jan 1, 2017
3.02 M USD
Jan 1, 2018
14.43 M USD
Jan 1, 2019
12.95 M USD
Jan 1, 2020
18.44 M USD
Jan 1, 2021
32.61 M USD
Jan 1, 2022
40.63 M USD
Jan 1, 2023
47.79 M USD
The Alpine Immune Sciences Current Liabilities history
YEARCurrent LiabilitiesYoY
47.79 MUSD+17.64%
40.63 MUSD+24.60%
32.61 MUSD+76.82%
18.44 MUSD+42.44%
12.95 MUSD-10.27%
14.43 MUSD+378.03%
3.02 MUSD-72.81%
11.10 MUSD+41.95%
7.82 MUSD+99.71%
3.92 MUSD-46.45%
7.31 MUSD+217.90%
2.30 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alpine Immune Sciences Stock analysis

What does Alpine Immune Sciences do? Alpine Immune Sciences Inc. is a biopharmaceutical company specializing in the research and development of immunotherapies. Founded in 2015, the company is based in Seattle, Washington and holds numerous patents in the field of immunology. Alpine's business model is to utilize clinical science and innovative technologies to revolutionize immunotherapy. The company combines antibodies and other immunological agents to significantly improve the effectiveness and safety of therapies. The company is divided into several divisions, each offering different products and services. One division focuses on the discovery of novel antibodies and other biological agents. Through various technology platforms, Alpine continuously develops groundbreaking therapies that have the potential to revolutionize the treatment of cancer, autoimmune diseases, and other illnesses. Another division of Alpine is dedicated to the field of immuno-oncology, specifically researching and developing immunotherapies against cancer. The main goal is to enhance the body's own immune defenses against cancer cells. Furthermore, Alpine also develops therapies for specific autoimmune diseases, where the body's immune system attacks its own cells and tissues. In this area as well, the company relies on combining different immunological agents to increase the effectiveness and safety of the therapy. One of Alpine's most well-known products is ALPN-101, a novel antibody that can be used in immunotherapy against cancer and autoimmune diseases. This antibody has the potential to improve the effectiveness and safety of existing therapies, contributing to the cure and relief of illnesses. Alpine Immune Sciences Inc. has an impressive track record, having made significant progress in the field of immunotherapy in a short period of time and establishing itself as a leading provider of innovative therapies. Additionally, Alpine has successfully formed partnerships with other companies and institutions to advance its research and development. Overall, Alpine Immune Sciences Inc. represents a forward-thinking and innovative approach to immunotherapy, with the potential to change the lives of millions of people worldwide. Alpine Immune Sciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alpine Immune Sciences stock

Current Liabilities of Alpine Immune Sciences is 47.79 M USD in 2023.

Current Liabilities of Alpine Immune Sciences changed from 40.63 M USD to 47.79 M USD, representing a 17.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Alpine Immune Sciences since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Alpine Immune Sciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Alpine Immune Sciences

All Key Metrics — Alpine Immune Sciences